N/A
Manufactured by Cipla USA Inc.
894 FDA adverse event reports analyzed
Last updated: 2026-04-15
ISOPROTERENOL HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Cipla USA Inc.. The most commonly reported adverse reactions for ISOPROTERENOL HYDROCHLORIDE include DRUG INEFFECTIVE, TORSADE DE POINTES, OFF LABEL USE, VENTRICULAR TACHYCARDIA, ELECTROCARDIOGRAM QT PROLONGED. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ISOPROTERENOL HYDROCHLORIDE.
Out of 409 classified reports for ISOPROTERENOL HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 894 FDA FAERS reports that mention ISOPROTERENOL HYDROCHLORIDE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DRUG INEFFECTIVE, TORSADE DE POINTES, OFF LABEL USE, VENTRICULAR TACHYCARDIA, ELECTROCARDIOGRAM QT PROLONGED, CARDIOGENIC SHOCK. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Cipla USA Inc. in connection with ISOPROTERENOL HYDROCHLORIDE. Always verify the specific product and NDC with your pharmacist.